Puerarin for OVX-induced postmenopausal osteoporosis in murine model: systematic review and meta-analysis.
Ovariectomy (OVX)-induced murine model are widely used for post-menopausal osteoporosis study. Our current study was conducted to systematically review and critically assess the bone mass improved effect of puerarin for treating OVX-induced postmenopausal osteoporosis in murine model. Literatures from PUBMED, EMBASE, and CNKI were searched from their inception date to January 9th, 2019. Two reviewers independently selected animal studies that evaluated the bone mass improved effect of puerarin compared with control in OVX-induced rats. Extracted data were analyzed by RevMan statistical software, and the methodological quality of each study was assessed. Eight studies with adequate randomization were included in the systematic review. Overall, puerarin could significantly improve bone mass as assessed using the bone mineral density (BMD); (eight studies, n=203; weighted mean difference, 0.05; 95% CI, 0.03-0.07; P<0.0001) using a random-effects model. There is no significant difference between puerarin and estrogen (seven studies, n=184; weighted mean difference, 0.00; 95% CI, -0.01 to 0.00; P=0.30). Puerarin showed upregulating effects on bone mass in OVX-induced postmenopausal osteoporosis in murine model. More studies of the effect of puerarin on bone density in OVX animals are needed.